Mailing Address:
Harvard Medical School
Department of Ambulatory Care and Prevention
133 Brookline Avenue, 6th Floor
Boston, MA 02215

Email:
Priscilla_Velentgas@harvardpilgrim.org

Phone: (617) 509-9957
Fax: (617) 859-8112

Priscilla Velentgas, Ph.D.

Dr. Velentgas is a Lecturer in the Department of Ambulatory Care and Prevention and an epidemiologist with expertise in pharmacoepidemiology, cardiovascular epidemiology, and cancer epidemiology. Her research interests include the safety of marketed pharmaceutical products and methods for dealing with confounding by indication. Her current research involves multi-site pharmacoepidemiology research using large administrative data systems.

Selected publications:
• Velentgas P, Sheffield R, Nordstrom B, Johnson ES, Do T, Seeger JA. A Systematic Review of Studies of Adherence with Medication Use: Focus on Persistence with Intraocular Pressure Lowering Medications in Glaucoma Management. Annals of Pharmacotherapy. [in press].
• Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety 2006.
• Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004. 44: 642-51.
• Velentgas P, Delzell E, Toeppen-Sprigg B, Holtshouser JL. Response to: Mortality among rubber chemical manufacturing workers by M.M. Prince et al. Am. J. Ind. Med. 2000. 37: 590-598.
• Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: subclinical cardiovascular disease and all-cause mortality. Arteriosclerosis, Thrombosis and Vascular Biology 2000; 20: 823-9.
• Velentgas P, Daling JR, Malone KE, Weiss NS, Williams MA, Self SG, Mueller BA. Pregnancy after breast cancer: outcomes and influence on mortality. Cancer 1999; 85(11): 2424-32.